Compile Data Set for Download or QSAR
Report error Found 476 Enz. Inhib. hit(s) with all data for entry = 13044
TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754501(1-(5-cyanopyridin-2-yl)-N-(2-(difluoromethoxy)-6-m...)
Affinity DataIC50: 1nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754489(N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(4-...)
Affinity DataIC50: 1nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754300(N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-...)
Affinity DataIC50: 1.30nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754419(1-(2-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl...)
Affinity DataIC50: 2nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754483(methyl 1-(5-(3-((2-(difluoromethoxy)-6-methylpyrid...)
Affinity DataIC50: 2nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754495(N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(5-...)
Affinity DataIC50: 2nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754637(1-(2-(1H-tetrazol-1-yl)acetyl)-N-(2-(difluorometho...)
Affinity DataIC50: 2nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754492(N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(3-...)
Affinity DataIC50: 2nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754507(1-(5-cyanopyrimidin-2-yl)-N-(2-(difluoromethoxy)-6...)
Affinity DataIC50: 2nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754699(N-(5-bromo-3-(difluoromethoxy)pyridin-2-yl)-3-(2-i...)
Affinity DataIC50: 2nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754696(N-(5-chloro-3-(difluoromethoxy)pyridin-2-yl)-3-(2-...)
Affinity DataIC50: 2nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754327(N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-...)
Affinity DataIC50: 2nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754709(N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(3-...)
Affinity DataIC50: 3nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754317((R)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1...)
Affinity DataIC50: 3nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754347(ethyl-3-(4-((2-(difluoromethoxy)-6-methylpyridin-3...)
Affinity DataIC50: 3nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754714(N3-(5-bromo-3-(difluoromethoxy)pyridin-2-yl)-N1-cy...)
Affinity DataIC50: 3nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754537(N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-...)
Affinity DataIC50: 3nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754711(N3-(5-chloro-3-(difluoromethoxy)pyridin-2-yl)-N1-c...)
Affinity DataIC50: 3nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754534(N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(5-...)
Affinity DataIC50: 3nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754309(N-(6-ethoxy-2-methoxypyridin-3-yl)-3-(2-isopropylp...)
Affinity DataIC50: 4nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754340(1-(2-cyanoethyl)-N-(2-(difluoromethoxy)-6-methylpy...)
Affinity DataIC50: 4nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754306(N-(2,6-dimethoxypyridin-3-yl)-3-(2-isopropylphenyl...)
Affinity DataIC50: 4nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754546(N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-...)
Affinity DataIC50: 4nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754658(N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(2-...)
Affinity DataIC50: 4nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754273(3-((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)c...)
Affinity DataIC50: 4nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754593(3-((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)c...)
Affinity DataIC50: 4nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754368(methyl 4-(4-((2-(difluoromethoxy)-6-methylpyridin-...)
Affinity DataIC50: 4nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754378(methyl (3-((2-(difluoromethoxy)-6-methylpyridin-3-...)
Affinity DataIC50: 4nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754504(1-(5-cyanopyridin-2-yl)-N-(2-(difluoromethoxy)pyri...)
Affinity DataIC50: 4nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754614(3-((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)c...)
Affinity DataIC50: 4nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754674(2-((4-((2-(difluoromethoxy)-6-methylpyridin-3-yl)c...)
Affinity DataIC50: 4.30nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754523(N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-...)
Affinity DataIC50: 4.60nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754304(N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(3-...)
Affinity DataIC50: 5nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754633(4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)ca...)
Affinity DataIC50: 5nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754279(1-(((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)...)
Affinity DataIC50: 5nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754325(1-(2-aminopropyl)-N-(2-(difluoromethoxy)-6-methylp...)
Affinity DataIC50: 5nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754708(N-(5-chloro-3-(difluoromethoxy)pyridin-2-yl)-3-(3-...)
Affinity DataIC50: 5nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754417(2-(4-((2-(difluoromethoxy)-6-methylpyridin-3-yl)ca...)
Affinity DataIC50: 5nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754288(Ethyl ((3-((2-(difluoromethoxy)-6-methylpyridin-3-...)
Affinity DataIC50: 5nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754416(1-(2-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl...)
Affinity DataIC50: 5nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754510(1-(5-cyanopyrimidin-2-yl)-N-(2-(difluoromethoxy)py...)
Affinity DataIC50: 5nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754588(4-(3-(2-cyclopentylphenyl)-3-((2-(difluoromethoxy)...)
Affinity DataIC50: 5nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754298(N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(2-...)
Affinity DataIC50: 5nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754425(4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)ca...)
Affinity DataIC50: 5nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754424(5-((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)c...)
Affinity DataIC50: 5nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754423(methyl (3-((2-(difluoromethoxy)-6-methylpyridin-3-...)
Affinity DataIC50: 5nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754640(1-(2-(2H-1,2,3-triazol-2-yl)acetyl)-N-(2-(difluoro...)
Affinity DataIC50: 5.60nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754677(2-((4-((2-(difluoromethoxy)-6-methylpyridin-3-yl)c...)
Affinity DataIC50: 6nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754403(methyl 4-((3-((2-(difluoromethoxy)-6-methylpyridin...)
Affinity DataIC50: 6nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

TargetLysophosphatidic acid receptor 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM754352(N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-...)
Affinity DataIC50: 6nMAssay Description:The Tango™ EDG2-bla U2OS cells are obtained from Invitrogen. These cells contain the human LPA1 receptor cDNA linked to a TEV protease site and a Gal...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/22/2025
Entry Details
US Patent

Displayed 1 to 50 (of 476 total ) | Next | Last >>
Jump to: